enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

3. Long-acting beta-adrenoceptor agonist - Wikipedia

   en.wikipedia.org/wiki/Long-acting_beta...

   This second medication in this combination is the synthetic inhaled corticosteroid fluticasone furoate. This product was approved by the FDA in May 2013 as once-daily inhaled therapy for the treatment of chronic obstructive pulmonary disease (COPD) with umeclidinium bromide: Anoro Ellipta.

4. Pulmonary drug delivery - Wikipedia

   en.wikipedia.org/wiki/Pulmonary_drug_delivery

   Pulmonary drug delivery is mainly utilized for topical applications in the lungs, such as the use of inhaled beta-agonists, corticosteroids and anticholinergic agents for the treatment of asthma and COPD, the use of inhaled mucolytics and antibiotics for the treatment of cystic fibrosis (CT) and respiratory viral infections, [1] and the use of inhaled prostacyclin analogs for the treatment of ...

5. Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma - AOL

   www.aol.com/news/glaxo-innovivas-trelegy-ellipta...

   With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

6. AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA - AOL

   www.aol.com/news/astrazenecas-triple-combo-copd...

   For premium support please call: 800-290-4726 more ways to reach us

7. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol ) [ 4 ] [ 5 ] and also as a triple-therapy ...